Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

Paclitaxel is a chemotherapeutic agent widely used for many types of malignancies.
However, when paclitaxel is used to treat tumors, patients commonly experience severe …

The peripheral nervous system comprises an infinity of neural networks that act in the
communication between the central nervous system and the most diverse tissues of the …

Patients receiving paclitaxel for cancer treatment often develop an acute pain syndrome
(paclitaxel‐associated acute pain syndrome, P‐APS), which occurs immediately after …

Paclitaxel‐induced peripheral neuropathy (PIPN) is often associated with neuropathic pain
and neuroinflammation in the central and peripheral nervous system. Antihypertensive drug …

Paclitaxel is among the most widely used anticancer drugs and is known to cause a dose-
limiting peripheral neurotoxicity, the initiating mechanisms of which remain unknown. Here …

Bacteria/virus‐induced chronic inflammation is involved in both tumor initiation and tumor
progression. Toll‐like receptor 4 (TLR4) has been implicated in the development of several …

Recent studies by us and others have shown that enhancer of zeste homolog-2 (EZH2), a
histone methyltransferase, in glial cells regulates the genesis of neuropathic pain by …

Chemotherapy-induced neurotoxicity is one of the most prevalent side effects in cancer
patients and survivors. Cognitive decline and peripheral neuropathy are the most common …

Background Paclitaxel is a taxane-based chemotherapeutic agent used as a treatment in
breast cancer. There is no effective prevention or treatment strategy for the most common …